Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase Ib/II, Multi-center Study of 4SC-202 in Combination With Pembrolizumab in Patients With Unresectable Stage III/Metastatic Stage IV Cutaneous Melanoma Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

NCT03278665 is registered in ClinicalTrials.gov with 4SC AG as lead sponsor.

NCT NCT03278665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03278665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase Ib/II, Multi-center Study of 4SC-202 in Combination With Pembrolizumab in Patients With Unresectable Stage III/Metastatic Stage IV Cutaneous Melanoma Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
Lead sponsor
4SC AG
Phase
Phase 1/2
Overall status
Completed
Start date
September 25, 2017
Completion date
February 2, 2022
Enrollment
40 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma